Preventing Central Nervous System Induced Nausea Through Use of Vitamin B12 Conjugation

Robert Doyle

Preventing Central Nervous System Induced Nausea Through Use of Vitamin B12 Conjugation

Department of Chemistry

Research output: Patent

Abstract

A method for the avoidance of side effects associated with glucagon-like peptide-1 receptor (GLP-1R) agonists through vitamin B12 conjugation prior to administration. Vitamin B12 may be bound to a GLP-1R agonist, such as exendin-4 (Ex4), to provide enhanced proteolytic stability while retaining GLP-1R agonism. The conjugate (B12-Ex4) also improves glucose tolerance without producing anorexia and malaise. A GLP-1R agonist that is resistant to DPP-IV degradation and does not penetrate readily into the CNS, but retains the enhanced pharmacokinetic and pharmacodynamic profile on pancreatic β-cells provide a pharmacological tool for glycemic control in type 2 diabetes mellitus (T2DM) patients without eliciting unwanted hypophagia and nausea.

Original language	English (US)
Patent number	10,695,434
Priority date	2/5/18
Filing date	2/5/19
State	Accepted/In press - Aug 8 2019

Cite this

@misc{b3fa6eda27634114bba360a6c7c01dd8,

title = "Preventing Central Nervous System Induced Nausea Through Use of Vitamin B12 Conjugation",

abstract = "A method for the avoidance of side effects associated with glucagon-like peptide-1 receptor (GLP-1R) agonists through vitamin B12 conjugation prior to administration. Vitamin B12 may be bound to a GLP-1R agonist, such as exendin-4 (Ex4), to provide enhanced proteolytic stability while retaining GLP-1R agonism. The conjugate (B12-Ex4) also improves glucose tolerance without producing anorexia and malaise. A GLP-1R agonist that is resistant to DPP-IV degradation and does not penetrate readily into the CNS, but retains the enhanced pharmacokinetic and pharmacodynamic profile on pancreatic β-cells provide a pharmacological tool for glycemic control in type 2 diabetes mellitus (T2DM) patients without eliciting unwanted hypophagia and nausea.",

author = "Robert Doyle",

year = "2019",

month = aug,

day = "8",

language = "English (US)",

type = "Patent",

note = "10,695,434",

}

TY - PAT

T1 - Preventing Central Nervous System Induced Nausea Through Use of Vitamin B12 Conjugation

AU - Doyle, Robert

PY - 2019/8/8

Y1 - 2019/8/8

N2 - A method for the avoidance of side effects associated with glucagon-like peptide-1 receptor (GLP-1R) agonists through vitamin B12 conjugation prior to administration. Vitamin B12 may be bound to a GLP-1R agonist, such as exendin-4 (Ex4), to provide enhanced proteolytic stability while retaining GLP-1R agonism. The conjugate (B12-Ex4) also improves glucose tolerance without producing anorexia and malaise. A GLP-1R agonist that is resistant to DPP-IV degradation and does not penetrate readily into the CNS, but retains the enhanced pharmacokinetic and pharmacodynamic profile on pancreatic β-cells provide a pharmacological tool for glycemic control in type 2 diabetes mellitus (T2DM) patients without eliciting unwanted hypophagia and nausea.

AB - A method for the avoidance of side effects associated with glucagon-like peptide-1 receptor (GLP-1R) agonists through vitamin B12 conjugation prior to administration. Vitamin B12 may be bound to a GLP-1R agonist, such as exendin-4 (Ex4), to provide enhanced proteolytic stability while retaining GLP-1R agonism. The conjugate (B12-Ex4) also improves glucose tolerance without producing anorexia and malaise. A GLP-1R agonist that is resistant to DPP-IV degradation and does not penetrate readily into the CNS, but retains the enhanced pharmacokinetic and pharmacodynamic profile on pancreatic β-cells provide a pharmacological tool for glycemic control in type 2 diabetes mellitus (T2DM) patients without eliciting unwanted hypophagia and nausea.

M3 - Patent

M1 - 10,695,434

Y2 - 2019/02/05

ER -

Preventing Central Nervous System Induced Nausea Through Use of Vitamin B12 Conjugation

Abstract

Fingerprint

Cite this